MESO – mesoblast limited - american depositary shares (US:NASDAQ)

News

Mesoblast Financial Results and Corporate Update Webcast
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Ryoncil® Net Revenues Increase for the Quarter to US$30M [Yahoo! Finance]
Ryoncil® Net Revenues Increase for the Quarter to US$30M
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com